Provident Financial ServicesNYSE: PFS

-- 27% relative risk reduction of progression or death with GRANITE vs. control in all treated population (HR=0.73 [90% CI, 0.44, 1.21]) -- -- 50% relative risk reduction of progression or death with GRANITE vs. control in low ctDNA subgroup (HR=0.50 [90% CI, 0.20-1.28]) --

Provident Financial Services, Inc. (NYSE:PFS ) Q3 2024 Earnings Conference Call October 30, 2024 10:00 AM ET Company Participants Adriano Duarte – Investor Relations Officer Tony Labozzetta – President and Chief Executive Officer Tom Lyons – Senior Executive Vice President and Chief Financial Officer Conference Call Participants Greg Zingone – Piper Sandler Billy Young – RBC Capital Tim Switzer – KBW Manuel Navas – D.A. Davidson Operator Thank you for standing by.

Although the revenue and EPS for Provident Financial (PFS) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Provident Financial (PFS) came out with quarterly earnings of $0.36 per share, missing the Zacks Consensus Estimate of $0.46 per share. This compares to earnings of $0.38 per share a year ago.

ISELIN, N.J., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Provident Financial Services, Inc. (NYSE:PFS) (the “Company”) reported net income of $46.4 million, or $0.36 per basic and diluted share for the three months ended September 30, 2024, compared to a net loss of $11.5 million, or $0.11 per basic and diluted share, for the three months ended June 30, 2024 and net income of $28.5 million, or $0.38 per basic and diluted share, for the three months ended September 30, 2023. For the nine months ended September 30, 2024, net income totaled $67.0 million, or $0.65 per basic and diluted share, compared to $101.1 million, or $1.35 per basic and diluted share, for the nine months ended September 30, 2023.

HONG KONG , Oct. 16, 2024 /PRNewswire/ -- Akeso Biopharma (9926.HK)  (" Akeso", the "Company" ) announced positive results in progression-free survival (PFS) and overall survival (OS) from its Phase 3 clinical study (COMPASSION-16/AK104-303). This study evaluated the efficacy of its independently developed PD-1/CTLA-4 bispecific antibody, 开坦尼® (cadonilimab), in combination with or without platinum-based chemotherapy and bevacizumab, compared to placebo with platinum-based chemotherapy and bevacizumab for first-line treatment of persistent, recurrent, or metastatic cervical cancer.

Funding is provided through the bank's Community Partnership Program Funding is provided through the bank's Community Partnership Program

VANCOUVER, BC, Aug. 8, 2024 /PRNewswire/ - New Pacific Metals Corp. (TSX: NUAG) (NYSE-A: NEWP) ("New Pacific" or the "Company") is pleased to report the filing of an independent Pre-Feasibility Study ("PFS") technical report for its Silver Sand project (the "Project") located in Potosi, Bolivia with an effective date of June 19, 2024 (the "PFS Technical Report"). The PFS Technical Report was prepared in accordance with the Canadian Securities Administrators' National Instrument 43-101 – Standards of Disclosure for Mineral Projects ("NI 43-101").

Provident Financial Services, Inc. (NYSE:PFS ) Q2 2024 Results Conference Call July 26, 2024 10:00 AM ET Company Participants Adriano Duarte - Head of Investor Relations Tony Labozzetta - President and CEO Tom Lyons - Senior EVP, CFO Conference Call Participants Mark Fitzgibbon - Piper Sandler Tim Switzer - KBW Billy Young - RBC Capital Markets Operator [Call Started Abruptly] I would now like to turn the call over to Adriano Duarte, Head of Investor Relations. Adriano. Please go ahead.